Insomnia: When to See a Doctor

What Is Insomnia and How Common Is It?

Insomnia is difficulty falling asleep, staying asleep, or waking too early, combined with daytime impairment, even when adequate sleep opportunity exists. It is one of the most common complaints in primary care. Population studies estimate that 10 to 15 percent of adults in the United States meet full diagnostic criteria for chronic insomnia disorder, while up to 30 percent report occasional insomnia symptoms 1.

Acute vs. Chronic Insomnia

Short-term (acute) insomnia lasts fewer than three months and is almost always tied to an identifiable stressor, a new medication, travel across time zones, or an acute illness. Most episodes resolve once the trigger passes.

Chronic insomnia disorder, as defined by the International Classification of Sleep Disorders, Third Edition (ICSD-3), requires sleep difficulty occurring at least three nights per week for at least three months, causing clinically significant distress or daytime impairment 2. The distinction matters because chronic insomnia warrants structured treatment rather than watchful waiting.

Who Is Most Affected?

Women are roughly 1.4 times more likely than men to report insomnia symptoms across the lifespan 1. Risk rises sharply during perimenopause, with prevalence estimates reaching 40 to 60 percent of women in that transition 3. Older adults, shift workers, and people with comorbid psychiatric or pain conditions also carry elevated risk.

What Causes Insomnia?

The 3-P model, predisposing, precipitating, and perpetuating factors, is the most widely used conceptual framework in sleep medicine for understanding why insomnia develops and why it persists 4.

Predisposing Factors

Some people are constitutionally wired toward hyperarousal. Trait anxiety, female sex, family history of insomnia, and a tendency toward rumination all raise baseline vulnerability. Neuroimaging and polysomnographic data suggest people with chronic insomnia show higher 24-hour whole-brain metabolic rates compared with normal sleepers 5.

Precipitating Factors

A specific trigger, job loss, bereavement, a medical diagnosis, starting a stimulating medication such as fluoxetine or prednisone, or even a single night of terrible sleep before an important event, launches most insomnia episodes. Caffeine consumed after 2 p.m. Delays sleep onset by an average of 40 minutes even in habitual coffee drinkers 6.

Perpetuating Factors

These are the behaviors and beliefs that keep insomnia going long after the original trigger has passed. They include:

• Spending excessive time in bed hoping to "catch up" on sleep
• Watching the clock repeatedly during the night
• Catastrophizing thoughts such as "I will be unable to function tomorrow"
• Irregular sleep-wake schedules, including sleeping in on weekends
• Alcohol used as a sleep aid (it fragments sleep architecture in the second half of the night) 7

CBT-I specifically targets perpetuating factors, which is why it produces more durable remission than sleep medication alone.

Medical and Psychiatric Causes

Secondary insomnia is insomnia occurring in the context of another condition. Common contributors include:

• Obstructive sleep apnea (OSA): fragmented sleep from repeated arousal
• Restless legs syndrome (RLS): an irresistible urge to move the legs at rest
• Gastroesophageal reflux disease (GERD): nocturnal acid events that disrupt sleep
• Chronic pain syndromes: fibromyalgia, arthritis, neuropathy
• Major depressive disorder and generalized anxiety disorder
• Hyperthyroidism
• Perimenopause and menopause (declining estrogen and progesterone alter thermoregulation and sleep architecture) 3

Treating the underlying condition usually improves sleep, but insomnia frequently requires its own direct treatment as well because perpetuating behaviors become self-sustaining.

When Should You Worry About Insomnia?

Poor sleep for a few nights is not a medical emergency. Several specific patterns, however, signal that a clinical evaluation should not be delayed.

The Three-Month Threshold

If your sleep difficulty has lasted three months or longer and occurs at least three nights per week, you meet criteria for chronic insomnia disorder 2. At that point, spontaneous resolution is unlikely without intervention. Schedule an appointment with your primary care provider or a board-certified sleep medicine physician.

Daytime Impairment That Is Interfering With Work or Safety

Insomnia is defined not just by nighttime symptoms but by their daytime consequences. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) requires at least one of the following: fatigue, impaired concentration or memory, mood disturbance, behavioral problems, reduced motivation, proneness to errors or accidents, or dissatisfaction with sleep 8. Drowsy driving is a specific safety concern. The National Highway Traffic Safety Administration estimates drowsy-driving crashes kill approximately 800 people per year in the U.S., though researchers at the AAA Foundation believe the true figure may be closer to 6,400 9.

Red-Flag Symptoms Requiring Prompt Evaluation

Seek evaluation without waiting three months if any of the following are present:

• A bed partner reports that you stop breathing, gasp, or snore loudly during sleep. This pattern suggests obstructive sleep apnea, which carries cardiovascular and metabolic consequences if untreated.
• You experience uncomfortable crawling sensations in your legs at rest, especially in the evening, with an irresistible urge to move them. This is the hallmark of restless legs syndrome.
• You act out vivid dreams physically, such as punching or shouting during sleep. REM sleep behavior disorder may indicate early neurodegeneration in some patients and warrants polysomnography 10.
• Insomnia began after starting a new medication. Many prescription drugs, including beta blockers, corticosteroids, SSRIs, stimulants, and certain antihypertensives, disrupt sleep architecture.
• You are experiencing suicidal ideation or severe depression alongside insomnia. Chronic insomnia roughly doubles the risk of a new major depressive episode 11. Same-day evaluation is appropriate.
• Insomnia is accompanied by significant weight gain, cold intolerance, or fatigue far out of proportion to sleep loss, which may suggest hypothyroidism.
• You are pregnant. Sleep fragmentation and insomnia affect 50 to 75 percent of pregnancies, and untreated insomnia in pregnancy is associated with increased rates of preterm birth and postpartum depression 12.

The HealthRX clinical team uses the following triage framework for insomnia:

| Duration | Frequency | Action | |---|---|---| | <3 months | Occasional | Sleep hygiene, stimulus control; monitor | | <3 months | 3+ nights/week with impairment | Primary care evaluation; consider CBT-I | | 3+ months | 3+ nights/week | Confirmed chronic insomnia; CBT-I first-line | | Any duration | Red-flag symptom present | Prompt evaluation; polysomnography if indicated |

How Is Insomnia Diagnosed?

Insomnia diagnosis is clinical. No single test confirms it, but a structured evaluation rules out competing diagnoses and guides treatment selection.

Clinical History and Sleep Diary

A physician will ask about sleep onset latency (how long it takes to fall asleep), wake after sleep onset (total minutes awake during the night), terminal wakefulness (early morning awakening), and total sleep time. Keeping a two-week prospective sleep diary before your appointment gives the clinician objective data that is often more accurate than memory 13.

The Pittsburgh Sleep Quality Index (PSQI) is a validated self-report questionnaire with a score above 5 indicating poor sleep quality. The Insomnia Severity Index (ISI), with scores ranging from 0 to 28, is commonly used to quantify severity, with a score of 15 or above indicating moderate-to-severe clinical insomnia 14.

Wrist Actigraphy

Consumer fitness trackers give a rough picture of sleep duration, but medical-grade wrist actigraphy worn for seven to fourteen nights provides validated estimates of sleep-wake timing and total sleep time. Actigraphy is particularly useful for identifying circadian rhythm disorders that mimic insomnia 13.

Polysomnography

A full in-lab sleep study is not routinely recommended for uncomplicated insomnia. The American Academy of Sleep Medicine recommends polysomnography when sleep apnea, periodic limb movement disorder, or REM sleep behavior disorder is suspected, or when the patient has failed standard therapy 15.

Laboratory Tests

Blood work is ordered when a medical cause is suspected. A thyroid-stimulating hormone (TSH) level screens for thyroid dysfunction. A complete blood count checks for anemia. In perimenopausal or menopausal women presenting with sleep complaints, estradiol (E2) and FSH measurements can confirm ovarian hormone status and guide decisions about hormone therapy 3.

Evidence-Based Treatments for Insomnia

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is the recommended first-line treatment for chronic insomnia in adults, regardless of age or comorbid conditions, per the 2017 American College of Physicians guideline 16. A meta-analysis of 20 randomized controlled trials showed CBT-I reduced sleep onset latency by a mean of 19 minutes and wake after sleep onset by 26 minutes, with remission rates of 57 to 59 percent at post-treatment assessment 17.

CBT-I components include:

• Sleep restriction therapy: Temporarily compressing time in bed to the estimated total sleep time, building sleep drive and consolidating sleep.
• Stimulus control: Using the bed only for sleep and sex, getting out of bed after 20 minutes of wakefulness.
• Sleep hygiene education: Consistent wake time, limiting caffeine after early afternoon, reducing bright light exposure in the hour before bed.
• Cognitive restructuring: Identifying and challenging dysfunctional beliefs about sleep.
• Relaxation techniques: Progressive muscle relaxation, diaphragmatic breathing.

Digital CBT-I programs (such as Sleepio) show remission rates comparable to therapist-delivered CBT-I in randomized trials, making them a practical option when in-person therapy is unavailable 18.

Pharmacotherapy

Medication is appropriate when CBT-I is unavailable, declined, or only partially effective, or for short-term management of acute insomnia. The American Academy of Sleep Medicine 2017 clinical practice guideline provides specific recommendations 15.

FDA-approved options:

• Suvorexant (Belsomra): A dual orexin receptor antagonist approved at 10 mg and 20 mg. In a Phase 3 trial (N=1,021), suvorexant 20 mg reduced wake after sleep onset by 22 minutes versus 10 minutes for placebo at three months 19.
• Lemborexant (Dayvigo): A newer orexin antagonist approved at 5 mg and 10 mg. In the SUNRISE-2 trial (N=949), lemborexant 10 mg improved sleep onset latency by 11.4 minutes compared with 4.7 minutes for placebo over six months 20.
• Eszopiclone (Lunesta): A non-benzodiazepine GABA-A receptor modulator approved for both sleep onset and sleep maintenance. A six-month randomized trial (N=788) showed sustained efficacy without tolerance development 21.
• Zolpidem (Ambien): Approved at 5 mg (women) and 5 to 10 mg (men) for sleep onset. The FDA lowered the recommended dose for women in 2013 after pharmacokinetic data showed higher next-morning blood levels in women, impairing driving ability 22.
• Low-dose doxepin (Silenor): A tricyclic antidepressant at the sub-antidepressant dose of 3 to 6 mg approved specifically for sleep maintenance insomnia. It has minimal next-day sedation compared with higher doses 15.

Benzodiazepines (temazepam, triazolam) carry risks of tolerance, dependence, and rebound insomnia and are not recommended for long-term use. The American Academy of Sleep Medicine guideline rates diphenhydramine (found in most over-the-counter sleep aids) as having insufficient evidence for efficacy and notes rapid development of tolerance 15.

Hormone Therapy and Insomnia

In women with menopause-related insomnia, systemic estrogen-progestogen therapy can reduce nocturnal awakenings by improving vasomotor control. The Menopause Society's 2023 position statement notes that hormone therapy is the most effective treatment for vasomotor symptoms and their associated sleep disruption, and that for women aged younger than 60 years or within 10 years of menopause onset, the benefit-risk profile is favorable for most women 23. CBT-I may still be needed alongside hormone therapy because sleep-new behaviors can persist even after hot flashes resolve.

Melatonin and Supplements

Melatonin at doses of 0.5 to 5 mg has modest evidence for jet-lag-related circadian disruption and delayed sleep-wake phase disorder, but evidence for chronic insomnia disorder is weak. A Cochrane review found melatonin reduced sleep onset latency by a mean of 7 minutes in insomnia populations, a statistically significant but clinically marginal effect 24. Ramelteon (Rozerem), a prescription melatonin receptor agonist, has FDA approval for sleep-onset insomnia and lacks abuse potential, making it a reasonable option for patients with a history of substance use disorder.

Sleep Hygiene: What Actually Works

Sleep hygiene alone rarely resolves chronic insomnia, but specific behaviors have measurable effects on sleep physiology and support other treatments.

Light and Temperature

Exposure to blue-spectrum light in the two hours before bed suppresses melatonin secretion by up to 88 percent 25. Screen dimmers and blue-light-blocking glasses reduce this effect but do not eliminate it. Bedroom temperature between 65 and 68 degrees Fahrenheit (18 to 20 degrees Celsius) facilitates the core body temperature drop required for sleep onset.

Exercise Timing

Moderate aerobic exercise improves polysomnographic sleep quality in adults with chronic insomnia. A randomized trial (N=17) found that 16 weeks of moderate-intensity aerobic exercise (four times per week) improved PSQI scores from 13.4 to 7.5 (P<0.001) 26. Vigorous exercise within one hour of bedtime may delay sleep onset in some individuals because of residual sympathetic activation.

Consistent Wake Time

A fixed morning wake time, even after a poor night, is the single most consistent behavioral recommendation across CBT-I protocols. It builds homeostatic sleep pressure for the following night and anchors the circadian rhythm. Sleeping in on weekends by more than 90 minutes has been associated with higher rates of social jetlag and metabolic dysfunction in population data 27.

Special Populations

Older Adults

Sleep architecture changes with age: slow-wave (deep) sleep decreases, sleep becomes more fragmented, and earlier circadian phase ("morningness") becomes more pronounced. These changes are normal, but they lower the threshold for insomnia disorder. CBT-I is effective in older adults, with meta-analytic data showing effect sizes comparable to younger populations 28. Benzodiazepines and sedating antihistamines carry greater risk of falls and cognitive impairment in adults over 65 and appear on the American Geriatrics Society Beers Criteria as potentially inappropriate medications 29.

Adolescents

Delayed sleep-wake phase disorder, characterized by a sleep onset time typically after midnight and inability to wake for early school start times, is common in adolescents. The American Academy of Sleep Medicine recommends light therapy, chronotherapy, and melatonin for circadian phase disorders rather than sedative-hypnotic medications in this age group 15.

Pregnancy

Pharmacological sleep aids should be avoided in the first trimester and used with caution thereafter. Doxylamine-pyridoxine (Diclegis/Bonjesta), FDA-approved for nausea and vomiting of pregnancy, has a long safety record, but its use specifically for insomnia is off-label. CBT-I adapted for pregnancy is the preferred approach 12.